Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

Bridel, C, van Wieringen, WN, Zetterberg, H, Tijms, BM, Teunissen, CE, Alvarez-Cermeño, JC, Andreasson, U, Axelsson, M, Bäckström, DC, Bartos, A, Bjerke, M, Blennow, K, Boxer, A, Brundin, L, Burman, J, Christensen, T, Fialová, L, Forsgren, L, Frederiksen, JL, Gisslén, M, Gray, E, Gunnarsson, M, Hall, S, Hansson, O, Herbert, MK, Jakobsson, J, Jessen-Krut, J, Janelidze, S, Johannsson, G, Jonsson, M, Kappos, L, Khademi, M, Khalil, M, Kuhle, J, Landén, M, Leinonen, V, Logroscino, G, Lu, C-H, Lycke, J, Magdalinou, NK, Malaspina, A, Mattsson, N, Meeter, LH, Mehta, SR, Modvig, S, Olsson, T, Paterson, RW, Pérez-Santiago, J, Romme Christensen, J, Sellebjerg, FT & and the NFL Group 2019, 'Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis' JAMA Neurology, bind 76, s. 1035-1048. https://doi.org/10.1001/jamaneurol.2019.1534

APA

Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., Alvarez-Cermeño, J. C., ... and the NFL Group (2019). Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurology, 76, 1035-1048. https://doi.org/10.1001/jamaneurol.2019.1534

CBE

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu C-H, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Romme Christensen J, Sellebjerg FT, and the NFL Group. 2019. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurology. 76:1035-1048. https://doi.org/10.1001/jamaneurol.2019.1534

MLA

Vancouver

Author

Bridel, Claire ; van Wieringen, Wessel N ; Zetterberg, Henrik ; Tijms, Betty M ; Teunissen, Charlotte E ; Alvarez-Cermeño, José C ; Andreasson, Ulf ; Axelsson, Markus ; Bäckström, David C ; Bartos, Ales ; Bjerke, Maria ; Blennow, Kaj ; Boxer, Adam ; Brundin, Lou ; Burman, Joachim ; Christensen, Tove ; Fialová, Lenká ; Forsgren, Lars ; Frederiksen, Jette L ; Gisslén, Magnus ; Gray, Elizabeth ; Gunnarsson, Martin ; Hall, Sara ; Hansson, Oskar ; Herbert, Megan K ; Jakobsson, Joel ; Jessen-Krut, Jan ; Janelidze, Shorena ; Johannsson, Gudmundur ; Jonsson, Michael ; Kappos, Ludwig ; Khademi, Mohsen ; Khalil, Michael ; Kuhle, Jens ; Landén, Mikael ; Leinonen, Ville ; Logroscino, Giancarlo ; Lu, Ching-Hua ; Lycke, Jan ; Magdalinou, Nadia K ; Malaspina, Andrea ; Mattsson, Niklas ; Meeter, Lieke H ; Mehta, Sanjay R ; Modvig, Signe ; Olsson, Tomas ; Paterson, Ross W ; Pérez-Santiago, Josué ; Romme Christensen, Jeppe ; Sellebjerg, Finn T ; and the NFL Group. / Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology : A Systematic Review and Meta-analysis. I: JAMA Neurology. 2019 ; Bind 76. s. 1035-1048.

Bibtex

@article{aa510aa8106b46e784367904efffb447,
title = "Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis",
abstract = "Importance: Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage. The influence of age and sex is largely unknown, and levels across neurological disorders have not been compared systematically to date.Objectives: To assess the associations of age, sex, and diagnosis with NfL in CSF (cNfL) and to evaluate its potential in discriminating clinically similar conditions.Data Sources: PubMed was searched for studies published between January 1, 2006, and January 1, 2016, reporting cNfL levels (using the search terms neurofilament light and cerebrospinal fluid) in neurological or psychiatric conditions and/or in HC.Study Selection: Studies reporting NfL levels measured in lumbar CSF using a commercially available immunoassay, as well as age and sex.Data Extraction and Synthesis: Individual-level data were requested from study authors. Generalized linear mixed-effects models were used to estimate the fixed effects of age, sex, and diagnosis on log-transformed NfL levels, with cohort of origin modeled as a random intercept.Main Outcome and Measure: The cNfL levels adjusted for age and sex across diagnoses.Results: Data were collected for 10 059 individuals (mean [SD] age, 59.7 [18.8] years; 54.1{\%} female). Thirty-five diagnoses were identified, including inflammatory diseases of the central nervous system (n = 2795), dementias and predementia stages (n = 4284), parkinsonian disorders (n = 984), and HC (n = 1332). The cNfL was elevated compared with HC in a majority of neurological conditions studied. Highest levels were observed in cognitively impaired HIV-positive individuals (iHIV), amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and Huntington disease. In 33.3{\%} of diagnoses, including HC, multiple sclerosis, Alzheimer disease (AD), and Parkinson disease (PD), cNfL was higher in men than women. The cNfL increased with age in HC and a majority of neurological conditions, although the association was strongest in HC. The cNfL overlapped in most clinically similar diagnoses except for FTD and iHIV, which segregated from other dementias, and PD, which segregated from atypical parkinsonian syndromes.Conclusions and Relevance: These data support the use of cNfL as a biomarker of neuroaxonal damage and indicate that age-specific and sex-specific (and in some cases disease-specific) reference values may be needed. The cNfL has potential to assist the differentiation of FTD from AD and PD from atypical parkinsonian syndromes.",
author = "Claire Bridel and {van Wieringen}, {Wessel N} and Henrik Zetterberg and Tijms, {Betty M} and Teunissen, {Charlotte E} and Alvarez-Cerme{\~n}o, {Jos{\'e} C} and Ulf Andreasson and Markus Axelsson and B{\"a}ckstr{\"o}m, {David C} and Ales Bartos and Maria Bjerke and Kaj Blennow and Adam Boxer and Lou Brundin and Joachim Burman and Tove Christensen and Lenk{\'a} Fialov{\'a} and Lars Forsgren and Frederiksen, {Jette L} and Magnus Gissl{\'e}n and Elizabeth Gray and Martin Gunnarsson and Sara Hall and Oskar Hansson and Herbert, {Megan K} and Joel Jakobsson and Jan Jessen-Krut and Shorena Janelidze and Gudmundur Johannsson and Michael Jonsson and Ludwig Kappos and Mohsen Khademi and Michael Khalil and Jens Kuhle and Mikael Land{\'e}n and Ville Leinonen and Giancarlo Logroscino and Ching-Hua Lu and Jan Lycke and Magdalinou, {Nadia K} and Andrea Malaspina and Niklas Mattsson and Meeter, {Lieke H} and Mehta, {Sanjay R} and Signe Modvig and Tomas Olsson and Paterson, {Ross W} and Josu{\'e} P{\'e}rez-Santiago and {Romme Christensen}, Jeppe and Sellebjerg, {Finn T} and {and the NFL Group}",
year = "2019",
doi = "10.1001/jamaneurol.2019.1534",
language = "English",
volume = "76",
pages = "1035--1048",
journal = "Archives of Neurology",
issn = "2168-6149",
publisher = "American Medical Association",

}

RIS

TY - JOUR

T1 - Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

T2 - A Systematic Review and Meta-analysis

AU - Bridel, Claire

AU - van Wieringen, Wessel N

AU - Zetterberg, Henrik

AU - Tijms, Betty M

AU - Teunissen, Charlotte E

AU - Alvarez-Cermeño, José C

AU - Andreasson, Ulf

AU - Axelsson, Markus

AU - Bäckström, David C

AU - Bartos, Ales

AU - Bjerke, Maria

AU - Blennow, Kaj

AU - Boxer, Adam

AU - Brundin, Lou

AU - Burman, Joachim

AU - Christensen, Tove

AU - Fialová, Lenká

AU - Forsgren, Lars

AU - Frederiksen, Jette L

AU - Gisslén, Magnus

AU - Gray, Elizabeth

AU - Gunnarsson, Martin

AU - Hall, Sara

AU - Hansson, Oskar

AU - Herbert, Megan K

AU - Jakobsson, Joel

AU - Jessen-Krut, Jan

AU - Janelidze, Shorena

AU - Johannsson, Gudmundur

AU - Jonsson, Michael

AU - Kappos, Ludwig

AU - Khademi, Mohsen

AU - Khalil, Michael

AU - Kuhle, Jens

AU - Landén, Mikael

AU - Leinonen, Ville

AU - Logroscino, Giancarlo

AU - Lu, Ching-Hua

AU - Lycke, Jan

AU - Magdalinou, Nadia K

AU - Malaspina, Andrea

AU - Mattsson, Niklas

AU - Meeter, Lieke H

AU - Mehta, Sanjay R

AU - Modvig, Signe

AU - Olsson, Tomas

AU - Paterson, Ross W

AU - Pérez-Santiago, Josué

AU - Romme Christensen, Jeppe

AU - Sellebjerg, Finn T

AU - and the NFL Group

PY - 2019

Y1 - 2019

N2 - Importance: Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage. The influence of age and sex is largely unknown, and levels across neurological disorders have not been compared systematically to date.Objectives: To assess the associations of age, sex, and diagnosis with NfL in CSF (cNfL) and to evaluate its potential in discriminating clinically similar conditions.Data Sources: PubMed was searched for studies published between January 1, 2006, and January 1, 2016, reporting cNfL levels (using the search terms neurofilament light and cerebrospinal fluid) in neurological or psychiatric conditions and/or in HC.Study Selection: Studies reporting NfL levels measured in lumbar CSF using a commercially available immunoassay, as well as age and sex.Data Extraction and Synthesis: Individual-level data were requested from study authors. Generalized linear mixed-effects models were used to estimate the fixed effects of age, sex, and diagnosis on log-transformed NfL levels, with cohort of origin modeled as a random intercept.Main Outcome and Measure: The cNfL levels adjusted for age and sex across diagnoses.Results: Data were collected for 10 059 individuals (mean [SD] age, 59.7 [18.8] years; 54.1% female). Thirty-five diagnoses were identified, including inflammatory diseases of the central nervous system (n = 2795), dementias and predementia stages (n = 4284), parkinsonian disorders (n = 984), and HC (n = 1332). The cNfL was elevated compared with HC in a majority of neurological conditions studied. Highest levels were observed in cognitively impaired HIV-positive individuals (iHIV), amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and Huntington disease. In 33.3% of diagnoses, including HC, multiple sclerosis, Alzheimer disease (AD), and Parkinson disease (PD), cNfL was higher in men than women. The cNfL increased with age in HC and a majority of neurological conditions, although the association was strongest in HC. The cNfL overlapped in most clinically similar diagnoses except for FTD and iHIV, which segregated from other dementias, and PD, which segregated from atypical parkinsonian syndromes.Conclusions and Relevance: These data support the use of cNfL as a biomarker of neuroaxonal damage and indicate that age-specific and sex-specific (and in some cases disease-specific) reference values may be needed. The cNfL has potential to assist the differentiation of FTD from AD and PD from atypical parkinsonian syndromes.

AB - Importance: Neurofilament light protein (NfL) is elevated in cerebrospinal fluid (CSF) of a number of neurological conditions compared with healthy controls (HC) and is a candidate biomarker for neuroaxonal damage. The influence of age and sex is largely unknown, and levels across neurological disorders have not been compared systematically to date.Objectives: To assess the associations of age, sex, and diagnosis with NfL in CSF (cNfL) and to evaluate its potential in discriminating clinically similar conditions.Data Sources: PubMed was searched for studies published between January 1, 2006, and January 1, 2016, reporting cNfL levels (using the search terms neurofilament light and cerebrospinal fluid) in neurological or psychiatric conditions and/or in HC.Study Selection: Studies reporting NfL levels measured in lumbar CSF using a commercially available immunoassay, as well as age and sex.Data Extraction and Synthesis: Individual-level data were requested from study authors. Generalized linear mixed-effects models were used to estimate the fixed effects of age, sex, and diagnosis on log-transformed NfL levels, with cohort of origin modeled as a random intercept.Main Outcome and Measure: The cNfL levels adjusted for age and sex across diagnoses.Results: Data were collected for 10 059 individuals (mean [SD] age, 59.7 [18.8] years; 54.1% female). Thirty-five diagnoses were identified, including inflammatory diseases of the central nervous system (n = 2795), dementias and predementia stages (n = 4284), parkinsonian disorders (n = 984), and HC (n = 1332). The cNfL was elevated compared with HC in a majority of neurological conditions studied. Highest levels were observed in cognitively impaired HIV-positive individuals (iHIV), amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and Huntington disease. In 33.3% of diagnoses, including HC, multiple sclerosis, Alzheimer disease (AD), and Parkinson disease (PD), cNfL was higher in men than women. The cNfL increased with age in HC and a majority of neurological conditions, although the association was strongest in HC. The cNfL overlapped in most clinically similar diagnoses except for FTD and iHIV, which segregated from other dementias, and PD, which segregated from atypical parkinsonian syndromes.Conclusions and Relevance: These data support the use of cNfL as a biomarker of neuroaxonal damage and indicate that age-specific and sex-specific (and in some cases disease-specific) reference values may be needed. The cNfL has potential to assist the differentiation of FTD from AD and PD from atypical parkinsonian syndromes.

U2 - 10.1001/jamaneurol.2019.1534

DO - 10.1001/jamaneurol.2019.1534

M3 - Review

VL - 76

SP - 1035

EP - 1048

JO - Archives of Neurology

JF - Archives of Neurology

SN - 2168-6149

ER -

ID: 58981167